Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | THRA | P10827 | 3/20 | 0.55 |
| ▸ | THRB | P10828 | 3/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.50 |
| ▸ | RARB | P10826 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | RARA | P10276 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22040784 | 1.00 | ALDH1A1 (0.70) | ALDH1A1GPR84HPGDHSD17B10THRA | |
| SCHEMBL28161011 | 0.98 | GPR84 (0.68) | ALDH1A1GPR84HPGDHSD17B10THRA | |
| SCHEMBL16050416 | 0.98 | GPR84 (0.72) | ALDH1A1GPR84HPGDHSD17B10THRA | |
| SCHEMBL28049655 | 0.96 | GPR84 (0.70) | ALDH1A1GPR84HPGDHSD17B10THRA | |
| SCHEMBL290207 | 0.91 | PTGS2 (0.67) | ALDH1A1GPR84HPGDHSD17B10THRA | |
| SCHEMBL16050465 | 0.90 | GPR84 (0.62) | ALDH1A1GPR84HPGDHSD17B10THRA | |
| SCHEMBL15199282 | 0.86 | ALDH1A1 (0.67) | ALDH1A1GPR84HPGDHSD17B10PPARA | |
| SCHEMBL28899619 | 0.86 | ALDH1A1 (0.67) | ALDH1A1GPR84HPGDHSD17B10PPARA | |
| SCHEMBL17678364 | 0.85 | GPR84 (0.71) | ALDH1A1GPR84HPGDHSD17B10PTGS2 | |
| SCHEMBL6801680 | 0.85 | ALDH1A1 (0.96) | ALDH1A1HPGDHSD17B10THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550066-B2 | Substituted aromatic compounds and related method for the treatment of fibrosis | PROMETIC PHARMA SMT LIMITED (GB) | 2020-02-04 | — | — | US | claimed |
| US-11524930-B2 | Substituted aromatic compounds and related method for the treatment of fibrosis | Liminal Biosciences Limited (GB) | 2022-12-13 | — | — | US | disclosed |
| US-11524930-B2 | Substituted aromatic compounds and related method for the treatment of fibrosis | Liminal Biosciences Limited (GB) | 2022-12-13 | — | — | US | disclosed |
| CN-110105200-B | Substituted aromatic compounds for treating fibrosis and related methods | 里米诺生物科学有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11185521-B2 | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | Liminal Biosciences Limited (GB) | 2021-11-30 | — | — | US | disclosed |
| US-11185521-B2 | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | Liminal Biosciences Limited (GB) | 2021-11-30 | — | — | US | disclosed |
| CN-107106526-B | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | 普罗米蒂克医药SMT有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | LIMINAL BIOSCIENCES LTD (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | LIMINAL BIOSCIENCES LTD (GB) | 2021-03-25 | — | — | US | disclosed |
| EP-3203998-B1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DIABETES | LIMINAL BIOSCIENCES LTD (GB) | 2021-03-10 | — | — | EP | disclosed |
| WO-2016054728-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016054726-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DIABETES | PROMETIC BIOSCIENCES INC. (CA) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016054726-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DIABETES | PROMETIC BIOSCIENCES INC. (CA) | 2016-04-14 | — | — | WO | disclosed |
| US-20160039736-A1 | Substituted Aromatic Compounds and Related Method for the Treatment of Fibrosis | Liminal Biosciences Limited (GB) | 2016-02-11 | — | — | US | disclosed |
| US-20160039736-A1 | Substituted Aromatic Compounds and Related Method for the Treatment of Fibrosis | Liminal Biosciences Limited (GB) | 2016-02-11 | — | — | US | disclosed |
| US-20160039736-A1 | Substituted Aromatic Compounds and Related Method for the Treatment of Fibrosis | Liminal Biosciences Limited (GB) | 2016-02-11 | — | — | US | disclosed |
| EP-2970089-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND RELATED METHOD FOR THE TREATMENT OF FIBROSIS | ProMetic BioSciences Inc. (CA) | 2016-01-20 | — | — | EP | disclosed |
| CN-105189438-A | Substituted aromatic compounds for treating fibrosis and related methods | PROMETIC BIOSCIENCES INC | 2015-12-23 | — | — | CN | disclosed |
| WO-2014138906-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND RELATED METHOD FOR THE TREATMENT OF FIBROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014138906-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND RELATED METHOD FOR THE TREATMENT OF FIBROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | COL1A1, CCNH, COL2A1 | ALDH1A1 129/4885GPR84 1983/4885HPGD 580/4885 |
| US-11524930-B2 | Substituted aromatic compounds and related method for the treatment of fibrosis | CFH, C5, C9 | ALDH1A1 640/4885GPR84 1802/4885HPGD 2870/4885 |
| US-10550066-B2 | Substituted aromatic compounds and related method for the treatment of fibrosis | CFH, C9, C5 | ALDH1A1 742/4885GPR84 1762/4885HPGD 2944/4885 |
| US-20160039736-A1 | Substituted Aromatic Compounds and Related Method for the Treatment of Fibrosis | CFH, C9, C5 | ALDH1A1 699/4885GPR84 2045/4885HPGD 3060/4885 |
| US-11185521-B2 | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | ADIPOR1, ADIPOR2, FN1 | ALDH1A1 1129/4885GPR84 632/4885HPGD 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.